Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Tinzaparin may effectively prevent VTE and major bleeding.

Cardiovascular Disease (CVD)

Novel Oral Anticoagulant Fast Tracked for Patients With ESRD and Atrial Fibrillation

Brian Park, PharmD

January 27, 2023

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.

Chronic Kidney Disease (CKD)

Empagliflozin Under Review for Patients With Chronic Kidney Disease

Brian Park, PharmD

January 25, 2023

The application is supported by data from the phase 3 EMPA-KIDNEY trial, which enrolled more than 6600 adults with CKD at risk of kidney disease progression.

Bladder Cancer

Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn

Brian Park, PharmD

December 9, 2022

The decision to withdraw the indication was made based on findings from the subsequent confirmatory phase 3 IMvigor130 trial.

Hemodialysis

FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia

Brian Park, PharmD

November 29, 2022

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.

Hyperphosphatemia

FDA Panel Votes on Tenapanor for Hyperphosphatemia in CKD

Brian Park, PharmD

November 18, 2022

For patients who tolerated and remained on therapy, the average treatment effect on serum phosphorus was about -0.7mg/dL.

Anemia

FDA Panel Votes on Daprodustat for Anemia of Chronic Kidney Disease

Brian Park, PharmD

October 28, 2022

The NDA was supported by data from the ASCEND clinical program, which included dialysis and nondialysis patients.

Cardiovascular Disease (CVD)

FDA Approves Wearable Furosemide Delivery System Furoscix for Outpatient Use

Brian Park, PharmD

October 20, 2022

Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, single-use, pre-programmed on-body infusor for outpatient self-administration.